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A B S T R A C T
Mushrooms can be used as a source of cosmeceutical ingredients. Agaricus bisporus and Pleurotus ostreatus
ethanolic extracts present important bioactive properties, but with some compounds showing easy oxidation and
degradation. In the present work, microencapsulation by atomization/coagulation technique was used to protect
the extracts. The obtained microspheres were characterised in terms of morphology, particle size distribution
and encapsulation efficiency. Microencapsulated extracts were incorporated into a semi-solid base cream and
their performance compared with the use of the free forms in terms of bioactivity, and in vitro release using the
cosmetic matrix and real time conditions (up to 6 months). The physico-chemical properties (colour and pH) of
the developed formulations were also monitored over the same time period. The cosmeceutical formulations
containing free extracts displayed bioactivity. For the formulations prepared with the encapsulated forms, the
release of the extracts was achieved and anti-tyrosinase and antimicrobial activities were observed, while for the
antioxidant activity, the extract release over the time was not sufficient to exert an effect. Overall, the use of
mushroom extracts in free or encapsulated forms can be an option in cosmeceutical formulations, and the en-
capsulated forms can allow a controlled release leading to bioactivity control.
1. Introduction
Due to consumer’s demands, safety of synthetic chemicals, and en-
vironmental limitations, personal care and cosmetic formulators are
increasingly interested in bioactive ingredients, namely those obtained
from natural sources with environmental friendly connotations, and
less toxic effects (Secchi et al., 2014). Natural additives such as phy-
tonutrients, algae and microbial metabolites, dairy products, minerals
and animal protein components are becoming increasingly applied in
cosmeceutical formulations (Taofiq et al., 2016a). The term cosme-
ceutical was first coined by Albert Kligman, over 30 years ago at the
National Scientific Meeting of the Society of Cosmetic Chemists, and
this emerging concept refers to the use of bioactive compounds with
drug like benefits either to improve skin appearance, suppress hy-
perpigmentation and provide anti-aging benefits (Bissett, 2009). The
cosmeceutical market in recent years has identified several compounds
from natural sources with potential to be used as cosmeceutical in-
gredients (Taofiq et al., 2016a). The most widely used bioactive com-
pounds are those that display multifunctional properties mainly anti-
oxidant, tyrosinase, collagenase and elastase inhibitors (Miyake et al.,
2010; Taofiq et al., 2017b, 2016b).
Mushrooms have been gaining a progressive importance in our diet
due to their rich nutritional composition and low caloric value.
Furthermore, mushrooms exert health promoting benefits derived from
their antioxidant, antitumour, antimicrobial, anti-inflammatory, anti-
tyrosinase, immunomodulator, antiatherogenic and hypoglycemic ac-
tivities, which can be attributed to different bioactive compounds in
their composition (e.g., phenolic compounds, terpenoids, poly-
saccharides, lectins, steroids, glycoproteins and lipids) (Heleno et al.,
2012; Reis et al., 2015; Taofiq et al., 2016c, 2015). Their use in the
development of nutraceuticals, alternative medicines and drug dis-
covery (Bishop et al., 2015; Money, 2016) have been extensively
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exploited, with their cosmeceutical significance gaining, gradually, at-
tention (Taofiq et al., 2017b, 2016a,b). According to a recent review
conducted by Taofiq et al. (2016a), mushrooms demonstrated high
potential to be used as cosmeceutical ingredients, with some commer-
cial products still referring the use of mushrooms extracts, alone or in
combination with other natural extracts/ingredients.
The use of natural ingredients by the cosmetic industry has been
encouraged in the past years; nevertheless, the incorporation of these
bioactive ingredients during product formulation can face several lim-
itations, namely instability due to the interference with other com-
pounds, sensitivity to pH and temperature, or propensity to degrada-
tion, which will result in the gradual loss of efficiency and effectiveness
along time (Casanova et al., 2016). To overcome such constraints,
several nano- and micro-technologies have been applied to design ef-
ficient delivery systems, not just in the cosmetic sector but also in the
food and pharmaceutical ones. Microencapsulation techniques employ
the use of polymeric materials to protect active principles (e.g. active
ingredients), conferring protection, thus improving stability, and/or
provide their gradual release over the time, assuring therapeutic
treatments at correct concentrations and at the target sites (dos Santos
et al., 2016). Biodegradable polymers such as poly(Ɛ-caprolactone)
(PCL), polylactic acid (PLA) poly-D, L-lactide-co-glycolide (PLGA),
chitosan, and diverse polysaccharides have been used to encapsulate
components such as vitamins, phenolic compounds, essential oils, pig-
ments and fragrances (dos Santos et al., 2016). Even though bioactive
compounds have been successfully microencapsulated using a wide
range of polymeric materials, real-time in vitro release of the micro-
particles often require runs over long time-periods, ranging from days,
weeks, months or even years. This has increased studies relating to
finding efficient methods to accelerate in vitro release studies of these
microencapsulated ingredients (Andhariya et al., 2017a).
Following recent studies conducted by Taofiq et al. (2016b), where
ethanolic extracts of Agaricus bisporus (J.E. Lange) Imbach, Lentinula
edodes (Berk.) Pegler and Pleurotus ostreatus (Jacq. ex Fr.) P. Kumm)
demonstrated cosmeceutical potential, A. bisporus and P. ostreatus, due
to their highest bioactivity, were selected to be used in the present
study. Thus, ethanolic extracts obtained from these mushroom species
were prepared and further microencapsulated by the atomization/
coagulation method with sodium alginate as the polymeric matrix. The
produced microspheres were fully characterised and thereafter in-
corporated in a base cosmetic cream. The bioactive and physicochem-
ical properties imparted by these microencapsulated extracts, com-
paratively with the use of the respective free forms, were evaluated
over a 6 months’ time period. These studies were performed to ascertain
stability of the prepared formulations, microencapsulated versus free
forms, and monitor the in vitro release profile of selected bioactive
compounds (phenolic acids and ergosterol) in base-cream formulations.
2. Materials and methods
2.1. Standards and reagents
Acetonitrile 99.9% was of high-performance liquid chromatography
(HPLC) grade from Lab-Scan (Lisbon, Portugal), methanol was of ana-
lytical grade and supplied by Pronalab (Lisbon, Portugal). 2, 2-
Diphenyl-1-picrylhydrazyl (DPPH) was obtained from Alfa Aesar (Ward
Hill, MA, USA). Dulbecco's modified Eagle's minimum essential medium
(DMEM), p-hydroxybenzoic, p-coumaric, protocatechuic and cinnamic
acids, fetal bovine serum (FBS), penicillin, streptomycin, Griess reagent
system (Promega), DMSO, sulphorodamine B (SRB), lipopolysaccharide
(LPS), 3,4-dihydroxy-L-phenylalanine (L-DOPA) and mushroom tyr-
osinase enzyme were obtained from Sigma-Aldrich Co. (Saint Louis,
MO, USA). Sodium alginate was provided by Fluka Chemie (USA),
calcium chloride and Tween 80 by Panreac (Spain). Muller Hinton
broth (MHB) and Tryptic Soy Broth (TSB) culture media were obtained
from Biomerieux (Marcy l’Etoile, France). Blood agar (7% sheep blood),
and MacConkey agar plates were purchased from Biomerieux Marcy
l’Etoile, France). The p-iodonitrotetrazolium chloride (INT) was pur-
chased from Sigma-Aldrich (Spruce Street; St. Louis, MO, USA) being
used as microbial growth indicator.
2.2. Mushroom species and preparation of ethanolic extracts
Fresh samples of A. bisporus and P. ostreatus were purchased from a
local supermarket in Bragança at the Northeast of Portugal. For each
mushroom species, the fruiting bodies were dried at 30 °C in an oven
and reduced to a fine powder (20 mesh) for further extraction and
analysis. Extraction was performed in a Soxhlet apparatus using 3.0 g of
the dried powder per 150mL of ethanol during 5–6 h. Thereafter, the
solvent was evaporated under reduced pressure (rotary evaporator
Büchi R-210, Flawil, Switzerland) to obtain dried ethanolic extracts.
2.3. Microencapsulation of the extracts
2.3.1. Microencapsulation procedure
The atomization/coagulation technique was employed to micro-
encapsulate the A. bisporus and P. ostreatus extracts, similarly to the
protocol reported by Caleja et al. (2017) with slight modifications.
Sodium alginate, in combination with calcium chloride (CaCl2), was
used. The microspheres were produced as follows: 100mg of the extract
were suspended in 20mL of distilled water in the presence of 100mg of
tween 80 as surfactant. The mixture was then homogenised for 20min
using a Unidrive X100 homogenizer (Ingenieurbüro CAT, Germany).
Afterwards, 400mg of sodium alginate was added to the suspension,
keeping this mixture under stirring until complete dissolution of algi-
nate. The produced solution was atomized in the NISCO Var J30 system
(Zurich, Switzerland) at a flow rate of 0.3mL/min and a nitrogen
pressure of 100mbar (Fig. 1). The atomized droplets were coagulated
by contacting with the aqueous solution of CaCl2 (250mL, concentra-
tion of 4% (w/v)) over a time-period of 4 h. The produced microspheres
were then recovered by filtration under reduced pressure, washed twice
with distilled water, and finally lyophilized and stored in the dark
conditions at 4 °C. For easy identification of the samples, the following
codes were assigned to each microparticle denoting the ingredient that
they contain: A- A. bisporus extract, P- P. ostreatus extract and E- empty
microparticles.
2.3.2. Microencapsulation efficiency, yield and load
Encapsulation efficiency (EE %): This parameter measures the ability
of the encapsulating material to properly encapsulate the bioactive
ingredient and can be achieved by analyzing the amount that has not
been encapsulated (in the present case, the cumulative amount of ex-
tract present in the coagulation solution and in the first washing solu-
tion) with respect to the theoretical amount calculated based on the
used formulation. Quantification was done by HPLC coupled to a
photodiode array detector (PDA) (Papadimitriou and Bikiaris, 2009).
The encapsulation efficiency was thereafter calculated using the fol-
lowing expression:
= ×
weight of the encapsulated bioactive
total weight of bioactive used in the formulation
EE (%) 100
Encapsulation yield: This parameter compares the total weight of the
produced microcapsules relative to the total weight of the atomized
material, being calculated using the following expression:
= ×
weight of produced micropheres
weight of the atomized formulation
EY (%) 100
Encapsulation load: This parameter measures the bioactive content
(%, w/w) present in the produced microspheres and can be calculated
as follows:
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= ×
weight of the encapsulated bioactive
weight of the produced micropheres
EL (%) 100
2.3.3. Microcapsules characterization
Microspheres were analysed by optical microscopy (OM) using a
Nikon Eclipse 50i microscope (Tokyo, Japan) equipped with a Nikon
Digital Sight camera and NIS Elements software for data acquisition.
OM analysis was applied to assess the size and morphology of the mi-
crospheres right after the atomization and during the coagulation stage.
The particle size distributions were determined by laser diffraction
using a Malvern Mastersizer 3000 laser equipped with a Hydro MV
dispersion unit (Malvern, UK). Data was obtained and treated with
Mastersizer software version 3.10. Water was used as the solvent for
sample dispersion. Five measurements were made to ensure reprodu-
cibility, and the results were expressed in volume and number, being
particle size results expressed as the percentiles of 10%, 50% and 90%.
The residual values were less than 1%. The span of the volume-based
size distribution was also determined using the expression (Dv90-
Dv10)/Dv50 (Barboza et al., 2014).
2.4. Development of the cosmeceutical formulations
A cosmetic and white cream, free from fragrances, colourants,
parabens, mineral oils, sodium lauryl sulphate (SLS), propylene glycol,
and ethoxylates, purchased from Fagron Iberica S.A.U. (Barcelona,
Spain) was used. According to the technical data available, this for-
mulation has been certified to be safe by the US Food and Drug
Administration (FDA), Regulation (EC) No 1907/2006—REACH and
the National Health Surveillance Agency (ANVISA) of Brazil.
In order to cover the magnitude of all the bioactive properties to be
evaluated, the base creams were incorporated at a content of 2.5-fold
the EC50 and MIC values of the free extracts (Table A1,
Supplementary material) which correspond to a scale of 25mg of
extract per gram of base cream. The extracts, and the prepared micro-
capsules, were individually formulated into the base cosmetic cream,
using continuous stirring until the mixture was fully homogenized. The
formulations were stored in tightly closed vials at 4 °C with samples
withdrawn periodically (up to 6 months) to determine the evolution of
the bioactive properties and changes in physicochemical parameters.
2.5. Evaluation of the bioactive properties of the developed cosmeceutical
formulations
For bioactivity evaluation, the prepared cosmeceutical formulations
were dissolved in a solution of 50% (v/v) DMSO at 400mg/mL for
antioxidant activity, and at 100mg/mL for anti-tyrosinase activity
evaluation. For antibacterial activity evaluation, a 5% (v/v) DMSO
solution was used, and the concentration was 400mg/mL.
2.5.1. Antioxidant activity
Solutions with concentrations ranging from 25 to 400mg/mL were
prepared from the stock solution of 400mg/mL described previously.
Two assays were used: DPPH scavenging activity and reducing power.
DPPH scavenging activity: For each cream formulation, 30 μL of each
prepared dilution were mixed with 270 μL of methanol containing
DPPH radicals (6× 10−5 mol/L). The mixture was allowed to stand in
the dark for 1 h. The absorbance was measured at 515 nm in a micro-
plate reader (ELX800 Bio-Tek Instruments, Inc.). The radical scaven-
ging activity (RSA) was calculated using the equation: % RSA =
[(ADPPH − AS)/ADPPH] × 100, where AS is the absorbance of the sample
solution and ADPPH is the absorbance of the DPPH solution. The con-
centrations responsible for 50% of RSA (EC50 values) were calculated
from the graphical representation of RSA percentage versus extract
concentration. Trolox was used as the positive control.
Reducing power: Samples of the prepared dilutions (0.5 mL) were
mixed with sodium phosphate buffer (200mmol/L, pH 6.6, 0.5 mL) and
potassium ferricyanide (1% w/v, 0.5mL), and further incubated at
50 °C for 20min. Trichloroacetic acid (10% w/v, 0.5 mL) was added
and 0.8 mL of the mixture was transferred to a 48-well plate, followed
by the addition of deionized water (0.8 mL), ferric chloride (0.1% w/v,
0.16mL). Finally, the absorbance was measured at 690 nm in the
above-mentioned microplate reader. The concentrations responsible for
50% of antioxidant activity (EC50 values) were calculated.
2.5.2. Anti-tyrosinase activity
Tyrosinase inhibition assay was performed using L-DOPA as sub-
strate according to the procedure described by Taofiq et al. (2016b).
The assay was carried using a 96-well microplate and solutions pre-
pared from the stock solution of 100mg/mL (100- 12.25mg/mL). Each
well was filled with 40 μL of the prepared solutions, 80 μL of a phos-
phate buffer (0.1M, pH 6.8), 40 μL of tyrosinase enzyme (60 units/mL),
and 40 μL of L-DOPA (3.5mM). The mixture was incubated for 10min
at 37 °C, and the absorbance measured at 475 nm using the aforesaid
Fig. 1. Nisco Var J30 microencapsulation unit used for microparticles preparation.
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microplate reader. Each sample was accompanied by a blank containing
all components except L-DOPA. The results were compared with a
control consisting of 50% DMSO in place of the sample. The percentage
of tyrosinase inhibition was calculated as follows: [(Acontrol − Asample)/
Acontrol] × 100. L-Ascorbic acid was used as the positive control.
2.5.3. Antimicrobial activity
2.5.3.1. Selected microbial strains. The bacterial strains were clinical
isolates obtained from patients hospitalized in various departments at
the Hospital Center of Trás-os-Montes and Alto Douro (Vila Real,
Portugal). Two Gram-negative bacteria (Escherichia coli and Proteus
mirabilis (isolated from urine), three Gram-positive bacteria
(Enterococcus faecalis (isolated from urine), methicillin-sensitive
Staphylococcus aureus (MSSA) (isolated from wound exudate), and
methicillin-resistant Staphylococcus aureus (MRSA) (isolated from
expectoration)), and a yeast, Candida albicans (isolated from urine)
were tested. All these microorganisms were incubated at 37 °C in
appropriate fresh medium for 24 h before analysis in order to
maintain the exponential growth phase.
2.5.3.2. Determination of the Minimal Inhibitory Concentration
(MIC). The determination of the minimal inhibitory concentration
(MIC) was performed by the microdilution method and the rapid p-
iodonitrotetrazolium chloride (INT) colorimetric assay as reported by
Taofiq et al. (2016b). The cosmeceutical formulations were dissolved in
an aqueous DMSO solution (50%) followed by the addition of the
required medium (TSB or MHB, according to the bacteria
requirements), making a solution of 400mg/mL at 5% DMSO. Then,
190 μL of this solution were added to each well of the 96-well
microplate and therefore submitted to successive dilutions over the
wells containing 90 μL of MHB or TSB media. Then, 10 μL of inoculum
(1.5×108 CFU/mL) were added to all the microplate wells. The plates
were then incubated at 37 °C, for 24 h, in an oven (Jouan, Berlin,
Germany). The MIC values were determined after adding INT (0.2 mg/
mL, 40 μL) followed by incubation at 37 °C for 30min. Viable
microorganisms reduced the yellow dye to a pink colour. MIC was
defined as the lowest extract concentration that prevented this change,
thus showing inhibition of bacterial growth.
2.6. Chemical characterization of the mushroom-based cosmeceutical
formulations
The cream formulations were subjected to extraction with methanol
for 30min, filtered, dried in a rotary evaporator, and re-dissolved in a
water:methanol mixture (80:20, v/v). The samples were further filtered
through a 0.22 μm nylon disposable filter and then analysed by ultra-
fast liquid chromatography (UFLC), model Shimadzu 20 A series
(Shimadzu Corporation, Kyoto, Japan) coupled to a PDA detector, for
phenolic acids identification and quantification. For ergosterol identi-
fication, the cosmeceutical formulations were directly dissolved in
methanol and filtered through a 0.22 μm nylon disposable filter and
then analysed by HPLC-UV (Knauer, Smartline system 1000, Berlin,
Germany). For easy identification of the samples, the following codes
were assigned to each cosmeceutical formulation denoting the con-
tained ingredient: BCAb- base cream with A. bisporus extract, BCPo-
base cream with P. ostreatus extract, BCMAb- base cream with micro-
particles of A. bisporus extract, BCMPo- base cream with microparticles
of P. ostreatus extract, BCEM- base cream with empty microparticles
(control), BC- base cream (control).
2.7. Physico-chemical parameters of the mushroom-based cosmeceutical
formulations
2.7.1. Colour evaluation
The colour evaluation of the cosmeceutical formulation was per-
formed using a colourimeter model CR-400 (Konica Minolta Sensing
Inc., Tokyo, Japan) that has been calibrated against a standard white
tile as described by Caleja et al. (2016). The colour was measured using
the L*a*b* system where l* is a measure of the lightness, a* is a measure
of the greenness/redness while b* is a measure of the blueness/yel-
lowness. Colour space values were registered using the data software
“Spectra Magic Nx” (version CM-S100W 2.03.0006)
2.7.2. pH and odour evaluation
The pH of each cosmeceutical formulation was evaluated directly
with a HI 99,161 pH-meter (Hanna Instruments, Woonsocket, Rhode
Island, USA), calibrated before each measurement. The samples were
also submitted to olfactory analysis using the human nose as the odour
detector, since there is no analytical technique that can completely
replace the human nose.
2.8. Statistical analysis
For all experiments concerning bioactive properties, chemical
composition and physicochemical properties, samples were analysed in
triplicate. The results are expressed as mean values ± standard de-
viation (SD). The differences among different samples were analysed
using one-way analysis of variance (ANOVA) followed by Tukey's
honestly significant difference post hoc test with α=0.05, coupled
with Welch's statistic. This treatment was carried out using SPSS v. 22.0
program.
3. Results and discussion
3.1. Microencapsulation of the extracts
Table 1 summarizes the results obtained for the encapsulation ef-
ficiency, yield, and load. The concentration of the phenolic acids and
related compounds in the coagulation and washing solutions was de-
termined to calculate the EE (%), conducting to values of 72.81 and
99.63% for A and P, respectively, corroborating the successful en-
capsulation of the extracts. The EY (%), which represent the effective-
ness of the process, conducted to values of 60.20 and 50.80% for A and
P, which might be considered satisfactory considering that the tech-
nique was applied at a laboratory scale. The EL%, which depicts the
content of bioactive in the microparticles was 14.56% and 19.92% for A
Table 1
Comparison of particle size distribution in terms of number and volume, encapsulation efficiency, load and yield of the microparticles prepared using alginate.
Samples EE (%) EL (%) EY (%) Particle size distribution Mean particle size (μm)
Volume distribution Number distribution Volume Number
D10 (μm) D50 (μm) D90 (μm) Span D10 (μm) D50 (μm) D90 (μm)
A 72.81 14.56 60.20 27.10 100.00 254.00 2.27 0.72 0.94 2.05 122.22 1.14
P 99.63 19.92 55.00 27.70 94.70 240.00 2.24 0.72 0.92 1.96 109.66 1.11
E na na 60.00 19.50 79.20 235.00 2.72 0.82 1.15 2.83 102.38 1.50
na: not applied; EE-encapsulation efficiency; EL-encapsulation load; EY-encapsulation yield.
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and P, respectively. It allows to determine the quantity of microspheres
needed to be incorporated in the semi solid base cream.
The surface morphology of the prepared microparticles, im-
mediately after production, was visualized by optical microscopy and
the respective images (acquired at magnifications of 40x, 100x and
400x) are shown in Fig. 2. It is possible to observe a consistent spherical
morphology with few particles displaying crumpled shapes of various
sizes (consistent with a polydisperse sample), and no agglomeration.
The lyophilized microspheres were rehydrated in distilled water and
analysed again (magnification of 100x). The final shape of the rehy-
drated microspheres was quite irregular, but despite their deformation,
the final size was close to that obtained immediately after encapsula-
tion.
The results for the particle size distributions, in number and volume,
represented in terms of percentiles (D10, D50 and D90) are presented in
Table 1. The respective average particle size (in number and volume)
are also presented in Table 1. The achieved average sizes in volume for
A, P and E were 122.22, 109.66 and 102.38 μm respectively. From the
analysis of the particle size distributions shown in Fig. 3, distributions
in number were unimodal (or proximately unimodal), whereas dis-
tributions in volume showed a bimodal pattern. Considering span
(dispersity) parameter which reveals how homogenous the particle’s
size is (Table 1), there is no significant dissimilarity among all three
produced types of microparticles.
3.2. Bioactivity of mushroom-based cosmeceutical formulations – use of
free forms
In the present work, the cosmeceutical potential of each prepared
formulation was investigated based on their ability to display anti-
oxidant, anti-tyrosinase and antimicrobial activities. The in vitro anti-
oxidant activity of the cosmeceutical formulations prepared with the
ethanolic extracts are presented in Table 2. The formulations revealed
both DPPH scavenging activity and reducing power. The antioxidant
activity decreased over the time, which can be partly attributed to the
oxidation of the extracts. A similar study was reported by Gezina et al.
(2015) in which the authors prepared semi-solid formulations con-
taining two species of Honey bush (Cyclopia maculata Vent and Cyclopia
genistoides Vent). The active bioflavonoids present in their hydro-
methanolic extracts were found to lack sufficient stability in semi-solid
formulations to sustain the antioxidant activity. The phenolic acids, and
related compounds composing the ethanolic extracts of P. ostreatus and
A. bisporus are listed in Table A2 (Supplementary material) (Taofiq
et al., 2016b). These compounds have been reported to contribute
significantly to the antioxidant activity (Heleno et al., 2015). The
quantification of these compounds in the corresponding semisolid for-
mulations are presented in Table 2. For the cosmeceutical formulations
prepared with A. bisporus extract (BCAb), and P. ostreatus extract
(BCPo), phenolic acids, related compounds and ergosterol revealed no
significant changes in their content over the storage time (6 months).
Considering that there was no significant loss of bioactive compounds
under the used storage temperature (4 °C), further studies are needed to
Fig. 2. Optical Microscopy analysis with magnifications of 40, 100 and 400x of the microspheres after 4 h of coagulation under stirring. with A, and P representing
samples prepared with A. bisporus and P. ostreatus respectively.
Fig. 3. Microparticles size distributions expressed as mean number distributions and volume distribution, with A, P and E representing samples prepared with A.
bisporus, P. ostreatus and empty microparticles respectively.
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be conducted at different environmental conditions (temperature and
relative humidity) to confirm this observation.
Another interesting potential of bioactive ingredients in cosmeceu-
ticals is their tyrosinase inhibition potential, making them suppressors
of melanin that largely contribute to the hyperpigmentation and pho-
toaging (Taofiq et al., 2016a). The search for tyrosinase inhibitors has
also intensified in the last decade due to the negative consequences
associated with the use of synthetic ingredients that present several
negative effects on skin (Taofiq et al., 2017a). In the present study, the
results for tyrosinase inhibition activity of the developed formulations
are presented in Table 2. For the formulations prepared with mushroom
extracts (BCAb and BCPo), an anti-tyrosinase activity was observed and
the results show that both formulations contain compounds that can
inhibit tyrosinase, thus indicating their potential to be used in hy-
perpigmentation correction formulations. Like what was observed with
the antioxidant activity; a gradual loss of tyrosinase inhibition activity
from time 0 to 6 months in the formulations prepared with mushroom
ethanolic extracts, was observed. This can be attributed to possible
interactions with the different ingredients present in the base for-
mulation along time.
The life span of cosmetic and personal care products has been ex-
tended using synthetic preservatives due to their broad spectrum of
antimicrobial activity, low price and to the fact that these compounds
do not origin degradation products that affect physico-chemical prop-
erties (colour, pH, viscosity) (Kerdudo et al., 2016). Over the years
some of these synthetic preservatives have become more controversial
because of some negative effects associated with their use. Bearing in
mind these challenges, cosmetic companies are now in search of non-
harmful alternatives for consumers, and bioactive compounds with
multifunctional properties are slowly been used for this purpose (Taofiq
et al., 2017a). In the present study, the antimicrobial activity of each
cosmeceutical formulation against Gram-negative, Gram-positive and
yeast strains is presented in Table 3. In all cases, the prepared for-
mulations were found to be effective against Gram-negative, Gram-
positive bacteria and Candida albicans. However, at the effective
minimum inhibitory concentration, the antimicrobial activity failed to
be maintained until time 6 months, highlighting a loss of bioactivity of
the extracts. However, the results suggest that the compounds present
in the studied extracts have the potential to be used as preservatives,
capable of preventing microbial contamination in cosmeceutical for-
mulations, but need strategies to increase effectiveness maintenance
along storage time.
It was possible to identify and quantify the amount of phenolic acids
and related compounds, initially present in the extracts, within each
prepared cosmeceutical formulation (Table 3). All the target com-
pounds were stable and there was no significant loss over the storage
time from 0 to 6 months. Concerning the bioactive properties, a loss of
activity was observed over time, pointing out that other compounds,
over the ones analysed in the extracts and formulations, might
contribute for their bioactivity.
3.3. Bioactivity of mushroom-based cosmeceutical formulations –real time
in vitro release of microencapsulated extracts
Real time in vitro release of bioactive compounds from polymeric
microspheres is typically done to evaluate control release at appropriate
environmental and physiological conditions. This process may, some-
times, take weeks, months, or even years (Andhariya et al., 2017b). The
real time in vitro release of the mushroom extracts loaded in the pre-
pared microparticles, was performed under controlled temperature
during a 6-month period. The microparticles prepared in the present
work showed high encapsulation efficiencies and the manifestation of
bioactivity, due to compounds release from the microparticles, was
evaluated on the base cream added with microencapsulated extracts.
From the obtained results, it can be seen that the formulations prepared
with BCMAb and BCMPo particles, respectively, did not display sig-
nificant antioxidant and antimicrobial effects up to month 6, which can
be due to a very slow release of the encapsulated bioactives, whose
concentration is not enough to exert a bioactive effect. The slow release,
makes the process suitable to be used in the design of cosmeceutical
formulations, whose shelf life span varies from months to even years.
Therefore, the gradual release ensures a continuous effectiveness
against microbial growth. However, and from the point of view of skin
beneficial effects, their slow release can be disadvantageous as the
formulated product may not release the bioactive compounds at the
required levels for the intended effect. Nevertheless, it is expected that
the application process of the cream favour mechanical disruption of
the capsules, and thus the prompt release of the protected bioactive
compounds on skin surface.
As regards the anti-tyrosinase activity, the released compounds
Table 2






Time 0 Time 3 Time 6 Time 0 Time 3 Time 6 Time 0 Time 3 Time 6
BCAb 25.1 ± 0.5* 89 ± 8* >100 347 ± 1b 380 ± 2a 385 ± 13a 69 ± 1b 69 ± 5b 74 ± 1a
BCPo 23 ± 2c 40 ± 3b 56 ± 1a 339 ± 2c 355 ± 2b 378 ± 6a 51 ± 1c 57.8 ± 0.6b 62 ± 2a
BCMAb >100 31 ± 1* 69 ± 3* >400 >400 >400 >400 >400 >400
BCMPo >100 46 ± 4 46 ± 1 >400 >400 >400 >400 >400 >400
BCEM >100 >100 >100 >400 >400 >400 >400 >400 >400
BC >100 >100 >100 >400 >400 >400 >400 >400 >400
In each row different letters mean significant differences between formulations (p < 0.05). When only two samples were present a Student´s t-test was used to
determine the significant difference between two different samples, with α=0.05. *Means a significant difference between the samples (p > 0.001).
Table 3
Phenolic acids and ergosterol content in the developed cosmeceutical for-
mulations.










BCAbT0 2.20 ± 0.07a nd nd 1.11 ± 0.01a
BCAbT3 2.19 ± 0.07a nd nd 1.10 ± 0.01a
BCAbT6 2.18 ± 0.03a nd nd 1.08 ± 0.01a
BCPoT0 8.84 ± 0.02ª 3.87 ± 0.02a 1.52 ± 0.02a 1.93 ± 0.01a
BCPoT3 8.82 ± 0.14ª 3.84 ± 0.06a 1.51 ± 0.07a 1.92 ± 0.03a
BCPoT6 8.80 ± 0.03ª 3.80 ± 0.07a 1.50 ± 0.02a 1.89 ± 0.03a
In each column different letters mean significant differences in bioactive
compounds content between formulations (p < 0.05).
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were sufficient to cause activity manifestation of the formulations at the
3rd month of storage, as shown in Table 2. From the anti-tyrosinase
bioactivity evolution profile presented in Fig. 4, it can be observed that
both formulations, BCMAb and BCMPo, showed comparable patterns
until the 3rd month of storage time (no bioactivity). After this time-
period they start to reveal significant activity (31 ± 1 and 46 ± 4mg/
mL, for BCMAb and BCMPo respectively) but with a decreasing profile
until the 6 months. In particular, BCMPo was able to maintain a more
sustained release (no significant decrease was observed), comparatively
with BCMAb that showed an important decrease up to the 6th month. As
expected BCEM did not show any contribution to the tested bioactiv-
ities. The results for the antimicrobial activity of each prepared for-
mulation are presented in Table 4. Most studies on bioactive com-
pounds release, consider various conditions such as temperature,
solvent, pH, presence of enzymes or even stirring rate (Burgess and
Shen, 2012). However, some of these conditions do not mimic the real
environment, or the mechanism behind the release, making the real-
time release evaluation, such as the assays done in the present work, an
important contribute despite the long time required. In what concerns
release profiles evaluation, Acosta et al. (2015) reported that the release
of polyphenols from olive extract microencapsulated with chitosan was
pH dependent, and the release rate at pH 7.4 doubled the one obtained
at pH 5.5. Hence, more studies need to be conducted to find the best
conditions that might promote the degradation of the polymeric ma-
terial allowing for a faster delivery of the bioactive compounds, when
applied.
3.4. Physico-chemical parameters
During product development, especially when bioactive ingredients
are added either to improve products shelf life or to functionalise the
formulations, several procedures need to be conducted to ascertain the
safety and efficacy of the product. Some of the preliminary tests include
pH, viscosity, colour and odour evaluation. Current cosmetic market
offers consumers a wide variety of choices; even numerous consumers
still prefer products with basic colour. Hence, cosmetics companies
have paid attention in managing colour display during product design.
In the present study, the evaluation of the physical and chemical sta-
bility of the prepared semisolid formulations in terms of pH and colour
was carried out during the storage period up to 6 months. Table 5
summarizes the pH values of each formulation and the behaviour in
terms of colour changes. Over the course of incubation, no significant
colour changes were observed suggesting that the compounds present
in the extracts were stable and their possible degradation did not lead to
Fig. 4. Extrapolated real time in vitro release profile of formulations designed
with microparticles (BCMAb- base cream with microparticles of A. bisporus
extract, BCMPo- base cream with microparticles of P. ostreatus extract and



































































































































































































































































































































































































































O. Taofiq et al. Industrial Crops & Products 124 (2018) 44–52
50
products imparting colour changes. From data on Table 5, it is possible
to conclude that the formulations incorporated with the mushroom
ethanolic extracts (BCAb and BCPo) presented lower level of lightness
(l*) as the storage time increase, and this may be due to oxidation of the
incorporated extracts. The colour coordinates for the formulations
prepared with microparticles revealed a deeper red (greater a* value)
mainly due to the contribution of alginate. Overall, the initial odour
and colour were maintained and without significant variations over the
course of storage, and these are crucial parameters during preliminary
stability testing analysis.
The rate of dermal absorption of topical formulations such as lotions
and creams are often influenced by the pH of the product. The skin
surface pH is around 5.5, and at this condition, the skin micro-flora is
maintained (Ali and Yosipovitch, 2013; Martínez-Pla et al., 2004). Most
reports have suggested that a pH between 3.5 and 6.5 can be considered
for cosmetic formulations because most of the pathogenic bacteria, such
as Staphylococcus aureus, thrive best at neutral pH levels (Ali and
Yosipovitch, 2013). In the present work, all the cosmeceutical for-
mulations presented a pH between 3.4 and 5.0 suggesting that these
formulations have a large pH range, that was maintained even after
months under storage. Samples were stored at 4 °C and the lack of a
significant pH variations is a clear indication of formulation stability.
However, because most of the products exhibit excellent stability at this
temperature, temperature variation studies are necessary at 50˚, 25 °C
and -10 °C in order to fulfil the cycle stability tests and to evaluate the
behaviour of the developed formulations under temperature stress
(Moraes and Ueoka, 2018).
4. Conclusion
Bioactive compounds from natural sources are considered to show
interesting bioactive properties that tend to affect skin structure and
function, and as such, it is necessary to develop effective biocompa-
tible/biodegradable systems to ensure topical delivery of these natural
active ingredients. The above findings reveal that ethanolic extracts of
A. bisporus and P. ostreatus, display strong antioxidant, antimicrobial
and anti-tyrosinase activities, mainly due to the contribution of their
bioactive components, being suitable as multifunctional cosmeceutical
ingredients. The atomization/coagulation technique was successfully
applied to encapsulate the bioactives. After incorporating of the ex-
tracts into the base cosmetic cream, they displayed bioactivity; even
with a decreasing pattern along the 6 months, for the free extracts. For
the microencapsulated extracts, no demonstration of significant anti-
oxidant and antimicrobial activity was observed, with anti-tyrosinase
bioactivity being displayed after 3 months. Key findings in the present
study revealed that it is important to study the release profile of the
bioactive compounds from the microspheres, under different environ-
mental conditions, in order to promote a faster release of the active
ingredient, which might be interesting for certain applications. Results
presented in the present work reveal the promising potential of mush-
room extracts in what concerns bioactivity and stability, hence, studies
related with in vitro skin permeation using models to determine topical
bioavailability of these bioactive ingredients will be conducted in future
work.
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